Anticoagulant drugs comprise a specific subcategory of antithrombotic agents that act to
inhibit blood coagulation at various stages, reducing clot development and ultimately …

Many populations suffer from thrombotic disorders such as stroke, myocardial infarction,
unstable angina and thromboembolic disease. Thrombus is one of the major threatening …

Herein, an electrocatalytic protocol for the synthesis of 2, 3-dihydroquinazolin-4 (1H)-one
has been disclosed. Methanol is activated and utilized as the C1 source to cyclize with 2 …

As a pathological coagulation process, thrombus can lead to many serious diseases,
including ischemic stroke, acute myocardial infarction (AMI), acute coronary syndrome …

Venous thromboembolism including deep vein thrombosis and pulmonary embolism is an
abundant and dangerous disease with significant relapse probability and mortality. In pursuit …

Enzymes involved in the coagulation process have received great attention as potential
targets for the development of oral anti-coagulants. Among these enzymes, coagulation …

An economical and efficient approach to pharmaceutically and biologically significant 2, 3‐
dihydroquinazolin‐4 (1H)‐ones has been disclosed. The one‐pot multicomponent reaction …

Approximately 900,000 people are affected by some sort of venous thromboembolic (VTE)
event every year in the United States. VTE diagnosis used to mean treatment with …

A series of novel quinazolinone derivatives bearing a disulfide bond were designed and
synthesized. Their in vitro antiproliferative activities were evaluated using CCK-8 assay …

Abstract Coagulation factor Xa (FXa), a serine endopeptidase is a common coagulation
factor activated as a result of the initiation of both intrinsic and extrinsic blood coagulation …